The 5,000-square-foot expansion responds to client demand, says president Robert Lee: “The market for services is growing, yet the supply of CMOs interested in taking on these complex drug products is not.”
Hospira's US injectables contract manufacturing unit reported a
sales jump of 32 per cent to $43.4m (€33m), however, this stellar
performance is not indicative of the strength of the unit or the
performance expected to follow...